New study tracks Long-Term safety of muscle stiffness drug namuscla

NCT ID NCT04616807

Completed Symptom relief Sponsor: Lupin Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study followed 53 adults with non-dystrophic myotonic disorders who were taking Namuscla (mexiletine) to manage muscle stiffness. Researchers monitored side effects and how often patients needed to reduce their dose or stop treatment over up to 36 months. The goal was to see if the drug remains safe and effective with long-term use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mexiletine (Namuscla)
What this could lead to: If successful, this study could confirm that Namuscla is safe and effective for long-term use in managing muscle stiffness.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It only includes 53 participants, and side effects or lack of effectiveness could still occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYOTONIC DYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myotonic dystrophy nondystrophic myotonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYOTONIC DYSTROPHY

Contacts and locations

Locations

CHRU Lille

Lille, 59000, France
Hôpital Universitaire de La Pitié Salpêtrière

Paris, Cedex, 13 75013, France
Institute of Neurology

London, England, WC1N 3BG, United Kingdom
Nottingham University Hospitals NHS Trust

Nottingham, England, NG7 2UH, United Kingdom
St. Josef-Hospital Klinikum der Ruhr Universitaet Bochum

Bochum, North Rhine-Westphalia, 44791, Germany
Universitätsklinikum Ulm, Klinik für Neurologie

Ulm, 89081, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.